Gilead Sciences raised list prices by 4.9% on more than a dozen drugs Saturday, including the bulk of its best-selling HIV medications, the biotech confirmed to BioPharma Dive.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,